Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 35 | 2024 | 577 | 9.380 |
Why?
|
| Kidney Glomerulus | 19 | 2025 | 85 | 6.500 |
Why?
|
| Nephrons | 14 | 2022 | 22 | 6.080 |
Why?
|
| Kidney | 20 | 2024 | 363 | 4.590 |
Why?
|
| Ferritins | 15 | 2024 | 63 | 4.570 |
Why?
|
| Kidney Diseases | 10 | 2022 | 170 | 4.030 |
Why?
|
| Contrast Media | 14 | 2024 | 101 | 3.520 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2023 | 188 | 1.800 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2021 | 170 | 1.770 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2020 | 89 | 1.660 |
Why?
|
| Animals | 40 | 2025 | 16695 | 1.360 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2024 | 1737 | 1.320 |
Why?
|
| Positron-Emission Tomography | 3 | 2024 | 93 | 1.200 |
Why?
|
| Nanoparticles | 5 | 2016 | 449 | 1.150 |
Why?
|
| Copper Radioisotopes | 2 | 2024 | 9 | 1.060 |
Why?
|
| Diabetic Nephropathies | 2 | 2025 | 74 | 1.040 |
Why?
|
| Image Enhancement | 5 | 2021 | 38 | 0.990 |
Why?
|
| Rats | 16 | 2024 | 3701 | 0.960 |
Why?
|
| Glomerular Filtration Rate | 6 | 2022 | 144 | 0.960 |
Why?
|
| Kidney Tubules | 2 | 2024 | 38 | 0.900 |
Why?
|
| Mice | 15 | 2025 | 6490 | 0.890 |
Why?
|
| Biocompatible Materials | 2 | 2024 | 106 | 0.880 |
Why?
|
| Materials Testing | 1 | 2024 | 99 | 0.860 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 522 | 0.790 |
Why?
|
| Gadolinium | 1 | 2022 | 30 | 0.770 |
Why?
|
| Rural Population | 1 | 2024 | 352 | 0.690 |
Why?
|
| Male | 21 | 2025 | 22779 | 0.670 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 1554 | 0.640 |
Why?
|
| Escherichia coli | 1 | 2023 | 461 | 0.640 |
Why?
|
| Syndactyly | 1 | 2019 | 1 | 0.630 |
Why?
|
| Humans | 27 | 2024 | 42163 | 0.630 |
Why?
|
| Brain | 2 | 2021 | 1452 | 0.590 |
Why?
|
| Computer Simulation | 1 | 2021 | 404 | 0.580 |
Why?
|
| Algorithms | 5 | 2021 | 508 | 0.520 |
Why?
|
| Drug Delivery Systems | 3 | 2014 | 273 | 0.510 |
Why?
|
| Ferric Compounds | 2 | 2014 | 62 | 0.490 |
Why?
|
| Organ Size | 4 | 2021 | 167 | 0.480 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 53 | 0.450 |
Why?
|
| Liver | 2 | 2016 | 503 | 0.430 |
Why?
|
| Renal Circulation | 3 | 2024 | 20 | 0.430 |
Why?
|
| Cations | 4 | 2019 | 49 | 0.430 |
Why?
|
| Cell Count | 1 | 2014 | 140 | 0.420 |
Why?
|
| Iron | 2 | 2016 | 247 | 0.400 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 129 | 0.390 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 1058 | 0.380 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 227 | 0.380 |
Why?
|
| Magnetics | 1 | 2012 | 43 | 0.370 |
Why?
|
| Premature Birth | 2 | 2025 | 94 | 0.370 |
Why?
|
| Nanomedicine | 1 | 2012 | 52 | 0.360 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 1804 | 0.350 |
Why?
|
| Apoferritins | 1 | 2010 | 5 | 0.340 |
Why?
|
| Enzyme Precursors | 1 | 2010 | 14 | 0.340 |
Why?
|
| Gentamicins | 2 | 2020 | 10 | 0.330 |
Why?
|
| Indomethacin | 2 | 2020 | 26 | 0.330 |
Why?
|
| Horses | 2 | 2023 | 28 | 0.320 |
Why?
|
| Nanostructures | 1 | 2012 | 158 | 0.320 |
Why?
|
| Hydrogels | 1 | 2010 | 55 | 0.320 |
Why?
|
| Oxides | 1 | 2010 | 97 | 0.310 |
Why?
|
| Rabbits | 2 | 2020 | 292 | 0.310 |
Why?
|
| Animals, Newborn | 2 | 2020 | 350 | 0.300 |
Why?
|
| Basement Membrane | 1 | 2008 | 26 | 0.290 |
Why?
|
| Aged | 4 | 2024 | 7982 | 0.280 |
Why?
|
| Genes, Reporter | 1 | 2008 | 148 | 0.270 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2025 | 126 | 0.240 |
Why?
|
| Kidney Function Tests | 1 | 2024 | 30 | 0.230 |
Why?
|
| Oxazines | 1 | 2024 | 32 | 0.220 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2021 | 18 | 0.220 |
Why?
|
| Hyperglycemia | 1 | 2025 | 60 | 0.220 |
Why?
|
| Monte Carlo Method | 2 | 2021 | 66 | 0.210 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2024 | 106 | 0.210 |
Why?
|
| Female | 8 | 2025 | 24018 | 0.210 |
Why?
|
| Particle Size | 1 | 2024 | 267 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2023 | 27 | 0.200 |
Why?
|
| Chemokine CX3CL1 | 1 | 2023 | 14 | 0.200 |
Why?
|
| Software | 3 | 2021 | 234 | 0.200 |
Why?
|
| Homeostasis | 1 | 2024 | 193 | 0.190 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 130 | 0.190 |
Why?
|
| Middle Aged | 4 | 2024 | 11819 | 0.190 |
Why?
|
| Biopsy, Needle | 1 | 2021 | 59 | 0.180 |
Why?
|
| Normal Distribution | 1 | 2021 | 14 | 0.180 |
Why?
|
| Urinary Tract | 1 | 2021 | 8 | 0.180 |
Why?
|
| Adult | 4 | 2024 | 13458 | 0.170 |
Why?
|
| Glioma | 1 | 2021 | 92 | 0.170 |
Why?
|
| Health Status | 1 | 2024 | 432 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2020 | 55 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 129 | 0.160 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 102 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 602 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2024 | 65 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 680 | 0.150 |
Why?
|
| Cell Differentiation | 1 | 2021 | 633 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2020 | 429 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 57 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1729 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 727 | 0.130 |
Why?
|
| Disease Progression | 1 | 2019 | 661 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 438 | 0.130 |
Why?
|
| Pattern Recognition, Automated | 1 | 2016 | 32 | 0.130 |
Why?
|
| Histology | 1 | 2015 | 1 | 0.120 |
Why?
|
| Adolescent | 2 | 2024 | 5950 | 0.120 |
Why?
|
| Pathology | 1 | 2015 | 8 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 2803 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2015 | 206 | 0.110 |
Why?
|
| Molecular Probe Techniques | 1 | 2013 | 7 | 0.110 |
Why?
|
| Artificial Intelligence | 1 | 2015 | 94 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2015 | 190 | 0.110 |
Why?
|
| Molecular Probes | 1 | 2013 | 23 | 0.110 |
Why?
|
| Young Adult | 2 | 2021 | 4936 | 0.100 |
Why?
|
| United States | 1 | 2024 | 5072 | 0.100 |
Why?
|
| Phantoms, Imaging | 2 | 2013 | 27 | 0.100 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 30 | 0.100 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2012 | 3 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2014 | 176 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2012 | 141 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2012 | 230 | 0.090 |
Why?
|
| Perfusion | 2 | 2021 | 39 | 0.090 |
Why?
|
| Monitoring, Physiologic | 2 | 2021 | 37 | 0.080 |
Why?
|
| Enteropeptidase | 1 | 2010 | 1 | 0.080 |
Why?
|
| Trypsinogen | 1 | 2010 | 1 | 0.080 |
Why?
|
| Macromolecular Substances | 1 | 2010 | 95 | 0.080 |
Why?
|
| Proteoglycans | 1 | 2010 | 49 | 0.080 |
Why?
|
| Tissue Engineering | 1 | 2010 | 72 | 0.080 |
Why?
|
| Linear Models | 1 | 2010 | 311 | 0.080 |
Why?
|
| Spinal Cord Injuries | 1 | 2010 | 68 | 0.080 |
Why?
|
| Polymers | 1 | 2010 | 151 | 0.070 |
Why?
|
| Manganese | 1 | 2010 | 89 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 196 | 0.070 |
Why?
|
| Pregnancy | 2 | 2025 | 1737 | 0.070 |
Why?
|
| Organic Anion Transport Protein 1 | 1 | 2024 | 1 | 0.060 |
Why?
|
| Rhabdomyolysis | 1 | 2024 | 2 | 0.060 |
Why?
|
| Xanthenes | 1 | 2024 | 12 | 0.060 |
Why?
|
| Podocytes | 1 | 2025 | 37 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2020 | 1516 | 0.060 |
Why?
|
| Gene Knockout Techniques | 1 | 2024 | 54 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2025 | 101 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2024 | 69 | 0.060 |
Why?
|
| Creatinine | 1 | 2024 | 102 | 0.060 |
Why?
|
| Fluorescence | 1 | 2024 | 113 | 0.050 |
Why?
|
| Organogenesis | 1 | 2021 | 16 | 0.050 |
Why?
|
| Diffusion | 1 | 2021 | 63 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2021 | 47 | 0.050 |
Why?
|
| Models, Animal | 1 | 2021 | 149 | 0.040 |
Why?
|
| Child | 2 | 2020 | 3381 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 143 | 0.040 |
Why?
|
| Stem Cells | 1 | 2021 | 151 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 303 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 692 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 324 | 0.040 |
Why?
|
| Critical Illness | 1 | 2018 | 46 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1010 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2021 | 722 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 850 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 960 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 1143 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2013 | 18 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 143 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 238 | 0.020 |
Why?
|
| Manganese Compounds | 1 | 2010 | 15 | 0.020 |
Why?
|
| Chlorides | 1 | 2010 | 59 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 3942 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 279 | 0.020 |
Why?
|